Adjuvant Treatment Strategies for Pancreatic Cancer

Journal of Gastrointestinal Surgery

Volumn 10, Issue 6, 2006, Pages 916-926

  Newman, Erika A ^a   Simeone, Diane M ^a   Mulholland, Michael W ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

adjuvant therapy; neoadjuvant therapy; Pancreas; pancreatic cancer

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE;

ADENOCARCINOMA; ADJUVANT THERAPY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC IMAGING; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HUMAN; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; PANCREAS TUMOR; PANCREATICODUODENECTOMY; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; CHOLANGIOPANCREATOGRAPHY, MAGNETIC RESONANCE; DEOXYCYTIDINE; DIAGNOSTIC IMAGING; HUMANS; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 33744914638     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gassur.2005.10.018     Document Type: Review

References (53)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
2. Riela A., Zinsmeister A.R., Melton III L.J., and Weiland L.H. Increasing incidence of pancreatic cancer among women in Olmsted County, Minnesota, 1940 through 1988. Mayo Clin Proc 67 (1992) 839-845
3. Niederhuber J.E., Brennen M.F., and Menck H.R. The National Cancer Data Base report on pancreatic cancer. Cancer 76 (1995) 1671-1677
4. Lowenfels A.B., Maisonneuve P., DiMagno E.P., et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 89 (1997) 442-446
5. Lowenfels A.B., Maisonneuve P., Cavallini G., et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 328 (1993) 1433-1437
6. Ghadirian P., Boyle P., Simard A., et al. Reported family aggregation of pancreatic cancer within a population-based control study in the Francophone community in Montreal, Canada. Int J Pancreatol 10 (1991) 183-196
7. Maringhini A., Ciambra M., Raimondo M., et al. Clinical presentation and ultrasonography in the diagnosis of pancreatic cancer. Pancreas 8 (1993) 146-150
8. Weirsema M.J., Norton I.D., and Clain J.E. Role of EUS in the evaluation of pancreatic adenocarcinoma. Gastrointest Endosc 52 (2000) 578
9. Mertz H.R., Sechopoulos P., Delbeke D., and Leach S.D. EUS, PET, and CT scanning for evaluation of pancreatic adenocarcinoma. Gastrointest Endosc 52 (2000) 367-371
10. Tierney W.M., Francis I.R., Eckhauser F., et al. The accuracy of EUS and helical CT in the assessment of vascular invasion by periampullary malignancy. Gastrointest Endosc 53 (2001) 182-188
11. Varghese J.C., Farrell M.A., Courtney G., et al. Role of MR cholangiopancreatograpy in patients with failed or inadequate ERCP. AJR Am J Roentgenol 173 (1999) 1527-1533
12. Steinberg W. The clinical utility of the CA19-9 tumor-associated antigen. Am J Gastroenterol 85 (1990) 350-355
13. Pleskow D.K., Berher H.J., Gyves J., et al. Evaluation of a serological marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med 110 (1989) 704-709
14. Goggins M. Molecular markers of early pancreatic cancer. J Clin Oncol 23 (2005) 4524-4531
15. Cao D., Hustinx S.R., Sui G., et al. Identification of novel highly expressed genes in pancreatic ductal adenocarcinoma through a bioinformatics analysis of expressed sequence tags. Cancer Biol Ther 3 (2005) 1081-1089
16. Koopman J, White CN, Zhang Z, et al. Serum markers in patients with resectable pancreatic adenocarcinoma: MIC-1 vs. CA19-9. Presented at Gastroenterology Digestive Diseases Week, Chicago, IL, May 14-19, 2005.
17. Koopman J., Buckhaults P., Brown D.A., et al. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res 10 (2004) 2386-2392
18. Saldinger P.F., Reilly M., Reynolds K., et al. Is CT angiography sufficient for prediction of resectability of periampullary neoplasms?. J Gastrointest Surg 4 (2000) 233-237
19. Tseng J.F., Raut C.P., Lee E., et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 8 (2004) 935-949
20. Gastrointestinal Tumor Study Group. A multi-institutional comparative trial of radiation therapy alone and in combination with 5-FU for locally unresectable pancreatic carcinoma. Ann Surg 189 (1979) 205-208
21. Roldan G.E., Gunderson L.L., Nagorney D.M., et al. External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer. Cancer 61 (1988) 1110-1116
22. Burris III H.A., Moore M.J., Andersen M.R., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15 (1997) 2403-2413
23. Tempero M., Plunkett W., Ruiz Van Haperen V., et al. Randomized phase II comparison of dose-intense gemcitabine: thirty minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21 (2003) 3402-3408
24. Stathopoulos G.P., Syrigos K., Polyzos G., et al. Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an Intergroup, multicenter, phase II study. Ann Oncol 15 (2004) 97-104
25. Louvet C., Andre G., Lledo P., et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 20 (2002) 1512-1518
26. Brembeck F.H., Schoppmeyer K., Leupold U., et al. A phase II pilot trial of 13-cis retinoic acid and interferon-alpha in patients with advanced pancreatic carcinoma. Cancer 83 (1998) 2317-2323
27. Yeo C.J., Cameron J.L., Lilemoe K.D., et al. Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients. Ann Surg 221 (1995) 721-723
28. Birkmeyer JD, Warshaw AL, Finlayson SRG, et al. Relationship between hospital volume and late survival after pancreaticoduodenectomy. Surgery 199;126:178-183.
29. Lim J.E., Chien M.W., and Earle C.C. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 237 (2003) 74-85
30. Sener S.F., Fremgen A., Menck H.R., et al. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 189 (1999) 1-7
31. Kalser M.H., and Ellenberg S.S. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120 (1985) 899-903
32. Klinkenbijl J.H., Jeekel J., Sahmoud T., et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of the pancreas and periampullary region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 230 (1999) 776-782
33. Neoptolemos J.P., Dunn J.A., Stocken D.D., et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomized controlled trial. Lancet 358 (2001) 1576-1585
34. Yeo C.J., Abrams R.A., Grochow L.B., et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single institution experience. Ann Surg 225 (1997) 621-633
35. A phase III study of pre and post chemoradiation 5-FU vs pre and post chemoradiation gemcitabine for postoperative adjuvant treatment of resected pancreatic adenocarcinoma. The Radiation Therapy Oncology Group (Website). Available at: http://www.rtog.org/members/protocols/97-04/97-04.pdf. Accessed July 10, 2005.
36. Bakkevold K.E., Arnesjo B., Dahl O., et al. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater-results of a controlled, prospective, randomized multicentre study. Eur J Cancer 29A (1993) 698-703
37. Takada T., Amano H., Yasuda H., et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95 (2002) 1685-1695
38. Oettle H., Arning M., Langrehr J., et al. A randomized study of gemcitabine versus observation as adjuvant treatment for pancreatic cancer: results of an interim safety analysis (abstract). Proc Am Soc Clin Oncol 20 (2001) 46
39. European Study Group for Pancreatic Cancer Trial 3. Adjuvant chemotherapies in operable pancreatic cancer. Available at: http://www.liv.ac.uk/surgery/Espac5.html. Accessed October 1, 2005.
40. Bosset J.F., Pavy J.J., Gillet M., et al. Conventional external irradiation alone as adjuvant treatment in resectable pancreatic cancer: results of a prospective study. Radiother Oncol 24 (1992) 191-194
41. Hosotani R., Kogire M., Arii S., et al. Results of pancreatectomy with radiation therapy for pancreatic cancer. Hepatogastroenterology 44 (1997) 1528-1535
42. Breslin T.M., Hess K.R., Harbison D.B., et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 8 (2001) 123-132
43. Mehta V.K., Fisher G., Ford J.A., et al. Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. J Gastrointest Surg 5 (2001) 27-35
44. Wolff R.A., Evans D.B., Crane C.H., et al. Initial results of preoperative gemcitabine-based chemoradiation for resectable pancreatic adenocarcinoma. Clin Oncol 21 (2002) 130a
45. Ammori J.B., Colletti L.M., Zalupski M.M., et al. Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J Gastrointest Surg 7 (2003) 766-772
46. Phillip P.A. Gemcitabine and platinum combinations in pancreatic cancer. Cancer 95 (2002) 908-911
47. Picozzi V.J., Kozarek R.A., and Traverso L.W. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 185 (2003) 476-480
48. Kaufman H.L., Di Vito J., and Horig H. Immunotherapy for pancreatic cancer: current concepts. Hematol Oncol Clin North Am 16 (2002) 159-197
49. Laheru D., and Jaffee E.M. Pancreas cancer immunotherapy: science driving clinical progress. Nat Rev Cancer 5 (2005) 459-467
50. Jaffee E., Hruban R.H., Biedrzycki B., et al. Novel allogenic granulocyte-macrophage colony-stimulating-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 19 (2001) 145-156
51. Laheru D., and Jaffee E.M. Immunotherapy for pancreatic cancer: science driving clinical progress. Nat Rev Cancer 5 (2005) 459-467
52. Reya T., Morrison S.J., Clarke M.F., et al. Stem cells, cancer, and cancer stem cells. Nature 414 (2001) 105-111
53. Tempero M, Behrman J, Ben-Joséf E. Pancreatic adenocarcinoma. National comprehensive cancer network. Practice Guidelines in Oncology-v.1.2005. Available at http://www.accn.org/professionals/cms/pdf/pancreatic.pdf.